A Single Center study evaluating efficacy, safety and cost savings of switching from infliximab originator (IFXor) to the biosimilar (BS) CT-P13 in rheumatoid arthritis, spondylarthritis and psoriatic arthritis patients
Latest Information Update: 05 Feb 2020
Price :
$35 *
At a glance
- Drugs Infliximab (Primary)
- Indications Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
- Focus Adverse reactions; Therapeutic Use
- 14 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism